Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001878223 | SCV002127455 | likely benign | Jeune thoracic dystrophy; Nephronophthisis | 2023-10-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002482480 | SCV002799561 | uncertain significance | Asphyxiating thoracic dystrophy 4; Nephronophthisis 12 | 2022-02-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004039609 | SCV004972678 | uncertain significance | Inborn genetic diseases | 2023-10-13 | criteria provided, single submitter | clinical testing | The c.121T>C (p.F41L) alteration is located in exon 2 (coding exon 2) of the TTC21B gene. This alteration results from a T to C substitution at nucleotide position 121, causing the phenylalanine (F) at amino acid position 41 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |